[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Alonso G T, Jimenez F P, Martinez T J, et al. SEOM-GETNE-TTCC clinical guideline thyroid cancer (2023)[J]. Clin Transl Oncol, 2024, 26(11): 2902-2916.
[3] 中华医学会核医学分会. ¹³¹I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.
[4] Singer M C, Marchal F, Angelos P, et al. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology[J]. Head Neck, 2020, 42(11): 3446-3459.
[5] Jhiang S M, Sipos J A. Na⁺/I^- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy[J]. Endocr Relat Cancer, 2021, 28(10): T167-T177.
[6] Jonklaas J. Impact of nasolacrimal dysfunction in thyroid cancer survivors[J]. Thyroid, 2022, 32(5): 483-485.
[7] Diamond-Rossi S A, Jonklaas J, Jensen R E, et al. Looking under the hood of “the Cadillac of cancers”: radioactive iodine-related craniofacial side effects among patients with thyroid cancer[J]. J Cancer Surviv, 2020, 14(6): 847-857.
[8] Woog J J. The incidence of symptomatic acquired lacrimal outflow obstruction among residents of Olmsted County, Minnesota, 1976-2000 (an american ophthalmological society thesis)[J]. Trans Am Ophthalmol Soc, 2007, 105: 649-666.
[9] Kloos R T, Duvuuri V, Jhiang S M, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2002, 87(12): 5817-5820.
[10] Burns J A, Morgenstern K E, Cahill K V, et al. Nasolacrimal obstruction secondary to I(¹³¹) therapy[J]. Ophthalmic Plast Reconstr Surg, 2004, 20(2): 126-129.
[11] Fonseca F L, Lunardelli P, Matayoshi S. Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma[J]. Arq Bras Oftalmol, 2012, 75(2): 97-100.
[12] Fard E A, Farzanefar S, Fallahi B, et al. Nasolacrimal duct obstruction as a complication of iodine-¹³¹ therapy in patients with thyroid cancer[J]. Nucl Med Commun, 2012, 33(10): 1077-1080.
[13] Song H, Jeong J, Ju Koh M. Epiphora after radioactive iodine therapy in a low-risk patient[J]. Clin Nucl Med, 2015, 40(6): 536-537.
[14] Qahtani K H, Asiri M, Tunio M A, et al. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases[J]. Clin Ophthalmol, 2014, 8: 2479-2484.
[15] Jonklaas J. Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction[J]. Thyroid, 2014, 24(12): 1806-1814.
[16] Lee J Y, Woo K I. Surgical risk prediction for nasolacrimal duct obstruction in radioactive iodine-treated thyroid cancer: a nationwide cohort study[J]. Thyroid, 2022, 32(5): 544-551.
[17] Yartsev V D, Solodkiy V A, Fomin D K, et al. Clinical and demographic characteristics of tearing in patients after radioiodine ablation for differentiated thyroid cancer[J]. Curr Eye Res, 2021, 46(9): 1320-1324.
[18] Yang L, Ma J, Lei P, et al. Advances in antioxidant applications for combating ¹³¹I side effects in thyroid cancer treatment[J]. Toxics, 2023, 11(6): 529.
[19] Koca G, Acar U, Atilgan H I, et al. Changes in conjunctival cytology and tear function tests with radioiodine treatment for hyperthyroidism[J]. Ann Nucl Med, 2013, 27(8): 694-699.
[20] Bianchi G, Solaroli E, Zaccheroni V, et al. Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment[J]. Horm Metab Res, 1999, 31(11): 620-624.
[21] Bhartiya U S, Raut Y S, Joseph L J, et al. Evaluation of the radioprotective effect of turmeric extract and vitamin E in mice exposed to therapeutic dose of radioiodine[J]. Indian J Clin Biochem, 2008, 23(4): 382-386.
[22] Fedorov A A, Atkova E L, Yartsev V D. Secondary acquired nasolacrimal duct obstruction as a specific complication of treatment with radioactive iodine (morphological study)[J]. Ophthalmic Plast Reconstr Surg, 2020, 36(3): 250-253.
[23] Lee J Y, Song H S, Kang M. Physiological uptake of radioactive iodine around an artificial eyeball observed with single-photon emission computed tomography/computed tomography after radioactive iodine treatment[J]. Nucl Med Mol Imaging, 2020, 54(4): 204-206.
[24] Yartsev V D, Sheremeta M S, Trukhin A A, et al. Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level[J]. Indian J Ophthalmol, 2023, 71(5): 1828-1832.
[25] Morgenstern K E, Vadysirisack D D, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients[J]. Ophthalmic Plast Reconstr Surg, 2005, 21(5): 337-344.
[26] Wu D, Plyku D, Kulkarni K, et al. The spectrum of 124I uptake in the lacrimal gland and nasolacrimal sac/duct on PET/CT imaging[J]. Nucl Med Commun, 2021, 42(3): 292-299.
[27] Bakheet S M, Hammami M M, Hemidan A, et al. Radioiodine secretion in tears[J]. J Nucl Med, 1998, 39(8): 1452-1454.
[28] Ali M J. Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO) [J]. Prog Retin Eye Res, 2023, 96: 101193.
[29] Ali M J, Vyakaranam A R, Rao J E, et al. Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT[J]. Ophthalmic Plast Reconstr Surg, 2017, 33(1): 13-16.
[30] Li N, Zhang W. Clinical characteristics of nasolacrimal duct obstruction after iodine therapy in differentiated thyroid cancer patients[J]. Ear Nose Throat J, 2023, 17: 1455613231170088.
[31] Rahmanipour E, Askari E, Ghorbani M, et al. Eye-related adverse events after I-131 radioiodine therapy: a systematic review of the current literature [J]. Endocr Pract, 2024, 30(8): 770-778.
[32] Homer N A, Desai K. Nasolacrimal duct obstruction following radioactive iodine: an update on counseling recommendations for thyroid cancer survivors[J]. Endocr Pract, 2025, 31(2): 176-179.
[33] Aydogan F, Ayhan Tuzcu E, Aydogan A, et al. Effect of radioactive iodine therapy on lacrimal gland functions in patients with hyperthyroidism[J]. Clin Nucl Med, 2014, 39(4): 315-318.
[34] Lee I T, Chen W, Chen Q, et al. Factors associated with radioactive iodine therapy-acquired nasolacrimal duct obstruction[J]. Endocr Pract, 2022, 28(12): 1210-1215.
[35] Lubitz C C, Kiernan C M, Toumi A, et al. Patient perspectives on the extent of surgery and radioactive iodine treatment for low-risk differentiated thyroid cancer[J]. Endocr Pract, 2021, 27(5): 383-389.
[36] Seo M, Lee H, Park N R, et al. Association between perinasal uptake on radioactive iodine whole-body scan and nasolacrimal duct obstruction[J]. Medicina (Kaunas), 2025, 61(7): 1165.
[37] Kay M D, Morris L F, Beazer A, et al. Primary nasolacrimal duct obstruction visualized on ¹²³I preablation scan for papillary thyroid carcinoma[J]. J Nucl Med Technol, 2020, 48(1): 77-78.
[38] Usmani S, Jain A, Riyami K, et al. Accumulation of ¹³¹Iodine in the nasolacrimal sac/duct after radioiodine therapy for papillary thyroid cancer[J]. J Pak Med Assoc, 2023, 73(3): 713-714.
[39] Suresh A, Esposito G, Davidson B, et al. Radioactive iodine treatment for thyroid cancer complicated by lacrimal sac retention of iodine[J]. JCEM Case Rep, 2024, 3(1): luae234.
[40] Yartsev V D, Atkova E L, Ekaterinchev M A. Topographic and anatomical features of the nasolacrimal duct obstruction due to radioiodine treatment[J]. Int Ophthalmol, 2023, 43(9): 3385-3390.
[41] Fonseca F L, Yamanaka P K, Kato J M, et al. Lacrimal system obstruction after radioiodine therapy in differentiated thyroid carcinomas: a prospective comparative study[J]. Thyroid, 2016, 26(12): 1761-1767.
[42] Alexander C, Bader J B, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma[J]. J Nucl Med, 1998, 39(9): 1551-1554.
[43] Padilla J P, Burkat C N, Morgenstern K E. Topical application of perchlorate: a toxicity study in rats[J]. Ophthalmic Plast Reconstr Surg, 2024, 40(2): 198-200.
[44] Sun G E, Hatipoglu B. Epiphora after radioactive iodine ablation for thyroid cancer [J]. Thyroid, 2013, 23(2): 243-245.
[45] Lee I T, Grice J V, Ji X, et al. A pilot nonrandomized controlled trial examining the use of artificial tears on the radioactivity of tears after radioactive iodine treatment for thyroid cancer[J]. Thyroid, 2024, 34(1): 82-87.
[46] Liang C, Wu C, Liu L, et al. Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy[J]. Int Ophthalmol, 2024, 44(1): 257.
[47] Şingar E, Akbulut A, Koca G, et al. The influencer effect of dexmedetomidine on radioiodine relevant to lacrimal gland impairment[J]. Int Ophthalmol, 2024, 44(1): 115.
[48] Koca G, Singar E, Akbulut A, et al. The effect of resveratrol on radioiodine therapy-associated lacrimal gland damage[J]. Curr Eye Res, 2021, 46(3): 398-407.
[49] Eksioglu U, Atilgan H I, Yakin M, et al. Antioxidant effects of vitamin D on lacrimal glands against high dose radioiodine-associated damage in an animal model[J]. Cutan Ocul Toxicol, 2019, 38(1): 18-24.
[50] Inomata D, Hoshi S, Alcântara C P, et al. Dacryoendoscopic recanalization of lacrimal passage obstruction/stenosis after radioiodine therapy for differentiated thyroid carcinoma[J]. Am J Ophthalmol Case Rep, 2022, 25: 101344.
[51] Kim Y, Lew H. Dacryoendoscopic findings of patients with lacrimal drainage obstruction associated with cancer treatment[J]. Korean J Ophthalmol, 2022, 36(6): 509-517.
[52] Sweeney A R, Davis G E, Chang S H, et al. Outcomes of endoscopic dacryocystorhinostomy in secondary acquired nasolacrimal duct obstruction: a case-control study[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(1): 20-25.